Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tavocept, BNP7787, Dimesna
LP-300 · 2 trials · 5 indications
Number of days or months from the date of randomization to the earliest of the documented disease progression based on the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria
Number of days or months between the randomization date and the date of death from all causes
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Tavocept (BNP7787) |
| 2 | PLACEBO_COMPARATOR | 0.9% Sodium Chloride Soln. |
| LP-300 in Combination with Pemetrexed and Carboplatin | EXPERIMENTAL | LP-300 (investigational drug) + Pemetrexed and Carboplatin (standard of care chemotherapies) Dosing occurs on Day 1 of a 21-day cycle. |
| Pemetrexed and Carboplatin (Standard of Care) | ACTIVE_COMPARATOR | Pemetrexed and Carboplatin Only (standard of care chemotherapies) Dosing occurs on Day 1 of a 21-day cycle. |
| Name | Type | Description |
|---|---|---|
| BNP7787 | DRUG | The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks. |
| Placebo | DRUG | The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks. |
| LP-300 | DRUG | LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion. |
| Pemetrexed | DRUG | Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion. |
| Carboplatin | DRUG | Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion. |
INCLUSION CRITERIA Histologically or cytologically documented metastatic breast cancer Measurable disease Performance Status; ECOG 0-2 More than 2 weeks since prior radiation therapy 14 days or more since prior therapy and recovered from all side effects For patients who progress while receivi...
LP-300 is being developed for the treatment of advanced lung adenocarcinoma, specifically in never smokers with advanced lung adenocarcinoma and non-small-cell lung cancer. It is an investigational small molecule studied in combination with carboplatin and pemetrexed in patients with this biomarker-selected form of lung cancer.
LP-300 is being developed by Lantern Pharma Inc., a biopharmaceutical company whose common stock trades under the ticker symbol LTRN. Lantern Pharma is the sponsor of the clinical program evaluating LP-300 in advanced lung adenocarcinoma.
LP-300 is in Phase 2 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 2 study is currently recruiting participants and is designed to enroll approximately 90 patients across the United States, Japan, and Taiwan.
LP-300 is being evaluated in the Phase 2 trial NCT05456256, titled A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma. The trial is actively recruiting, is randomized and active-controlled, and has an estimated enrollment of 90 participants aged 18 years and older.
The Phase 2 trial NCT05456256 is a randomized, active-controlled study evaluating LP-300 in combination with carboplatin and pemetrexed in never smokers with advanced lung adenocarcinoma. It is not double-blinded, enrolls approximately 90 patients, and is recruiting in the United States, Japan, and Taiwan.
The Phase 2 trial NCT05456256 enrolls adults aged 18 years and older of any sex with advanced lung adenocarcinoma, specifically never smokers. The study is biomarker-selected and does not accept healthy volunteers. It is recruiting at sites in the United States, Japan, and Taiwan.